Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $41.32, marking a -0.41% move from the previous day.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
by Zacks Equity Research
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
by Zacks Equity Research
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe
by Zacks Equity Research
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
Best Single Trading Day in Months for Dow, Nasdaq, S&P
by Mark Vickery
The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
by Zacks Equity Research
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development
by Zacks Equity Research
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill
by Zacks Equity Research
Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.
Pre-Markets Back to Green Ahead of Economic & Earnings Data
by Mark Vickery
After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.
Pfizer (PFE) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
Top Analyst Reports for Pfizer, American Tower & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), American Tower Corporation (AMT), and Intuitive Surgical, Inc. (ISRG).
Cousins Properties' (CUZ) Heights Union Buyout Fails to Drive Stock
by Zacks Equity Research
The acquisition of Heights Union is in line with Cousins Properties' (CUZ) efforts to enhance its portfolio quality with trophy assets.